Intra-Cellular Therapies (ITCI) shares rallied 34.1% in the last trading session to close at $127.19. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 14.3% gain over the past four weeks.The surge in stock price came after pharma giant J&J announced its intent to acquire all outstanding shares of ITCI for $132 per share in cash, aggregating to nearly $14.6 billion. The deal is expected to be completed before t ...